Aditya Kulkarni, Jianli Zhou, Neha Biyani, Umesh Kathad, Partha P Banerjee, Shiv Srivastava, Zsombor Prucsi, Kamil Solarczyk, Kishor Bhatia, Reginald B Ewesuedo, Panna Sharma
Homologous recombination (HR) related gene alterations are present in a significant subset of prostate, breast, ovarian, pancreatic, lung and colon cancers rendering these tumors as potential responders to specific DNA damaging agents. A small molecule acylfulvene prodrug, LP-184, metabolizes to an active compound by the oxidoreductase activity of enzyme Prostaglandin Reductase 1 (PTGR1), which is frequently elevated in multiple solid tumor types. Prior work demonstrated that cancer cell lines deficient in a spectrum of (DNA damage repair) DDR pathway genes show increased susceptibility to LP-184...
April 17, 2024: Cancer Res Commun